CA3095893A1 - Use of cladribine for treating autoimmune neuromuscular disease - Google Patents

Use of cladribine for treating autoimmune neuromuscular disease Download PDF

Info

Publication number
CA3095893A1
CA3095893A1 CA3095893A CA3095893A CA3095893A1 CA 3095893 A1 CA3095893 A1 CA 3095893A1 CA 3095893 A CA3095893 A CA 3095893A CA 3095893 A CA3095893 A CA 3095893A CA 3095893 A1 CA3095893 A1 CA 3095893A1
Authority
CA
Canada
Prior art keywords
cladribine
composition
treatment
dose
myasthenia gravis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095893A
Other languages
English (en)
French (fr)
Inventor
Konrad REJDAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chord Therapeutics SA
Original Assignee
Chord Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics SA filed Critical Chord Therapeutics SA
Publication of CA3095893A1 publication Critical patent/CA3095893A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CA3095893A 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease Pending CA3095893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
GB1711800.1 2017-07-21
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (1)

Publication Number Publication Date
CA3095893A1 true CA3095893A1 (en) 2019-01-24

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095893A Pending CA3095893A1 (en) 2017-07-21 2018-06-28 Use of cladribine for treating autoimmune neuromuscular disease

Country Status (16)

Country Link
US (2) US12171775B2 (https=)
EP (2) EP4292663A3 (https=)
JP (1) JP7186214B2 (https=)
CA (1) CA3095893A1 (https=)
DK (1) DK3654989T3 (https=)
ES (1) ES2974423T3 (https=)
FI (1) FI3654989T3 (https=)
GB (1) GB2564717A (https=)
HR (1) HRP20240282T1 (https=)
HU (1) HUE066238T2 (https=)
LT (1) LT3654989T (https=)
PL (1) PL3654989T3 (https=)
PT (1) PT3654989T (https=)
RS (1) RS65246B1 (https=)
SI (1) SI3654989T1 (https=)
WO (1) WO2019016505A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
TW202541818A (zh) 2023-12-14 2025-11-01 瑞士商亞利斯貿易公司 用於治療重症肌無力之克拉屈濱(cladribine)療程

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
AU2003287664A1 (en) * 2002-11-22 2004-06-18 Transclick, Inc. System and method for language translation via remote devices
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
JP7186214B2 (ja) 2022-12-08
JP2020527156A (ja) 2020-09-03
RS65246B1 (sr) 2024-03-29
HRP20240282T1 (hr) 2024-05-10
US20250302858A1 (en) 2025-10-02
WO2019016505A1 (en) 2019-01-24
DK3654989T3 (da) 2024-02-26
EP4292663A2 (en) 2023-12-20
EP4292663A3 (en) 2024-03-20
HUE066238T2 (hu) 2024-07-28
PL3654989T3 (pl) 2024-05-20
PT3654989T (pt) 2024-02-28
LT3654989T (lt) 2024-03-25
GB2564717A (en) 2019-01-23
GB201711800D0 (en) 2017-09-06
SI3654989T1 (sl) 2024-06-28
EP3654989A1 (en) 2020-05-27
ES2974423T3 (es) 2024-06-27
US20200163986A1 (en) 2020-05-28
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
EP3654989B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
US20250302858A1 (en) Use of cladribine for treating autoimmune neuromuscular disease
AU2015212613B2 (en) Use of cladribine for treating neuromyelitis optica
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
US20230270743A1 (en) Use of btk inhibitors in the treatment of diseases
HK40106667A (en) Use of cladribine for treating autoimmune neuromuscular disease
HK40031112A (en) Use of cladribine for treating autoimmune neuromuscular disease
HK40031112B (en) Use of cladribine for treating autoimmune neuromuscular disease
EP1032402B1 (en) Use of citicoline for the treatment of multiple sclerosis (MS)
RU2854955C1 (ru) Применение кладрибина для лечения иммунных заболеваний головного мозга
RU2837046C1 (ru) Применение ингибиторов btk при лечении заболеваний
US20020198172A1 (en) Method of treating motor neuron diseases and demyelinating diseases with citicoline
GB2601786A (en) Use of cladribine for treating immune brain disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240927

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250225

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250225

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250416

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250813

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250825

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250904

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250929

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250929